Literature DB >> 30009121

Comparison of Male and Female Prolactinoma Patients Requiring Surgical Intervention.

Frederick Yoo1, Carmen Chan1, Edward C Kuan1, Marvin Bergsneider2, Marilene B Wang1.   

Abstract

Objectives  Prolactinomas are the most common functional pituitary adenoma. Symptoms of a prolactinoma stem from hormonal causes (menstrual irregularities, galactorrhea, and reduced libido) or from tumor mass effect (visual changes and headache). Gender differences have been noted in prolactinomas, with males presenting with larger tumors and sequelae of mass effect, while females present commonly with hormonal symptoms. The purpose of this study is to evaluate differences in patient and disease characteristics, and outcomes between male and female prolactinoma patients undergoing surgery. Design  This was a retrospective chart review. Setting  This was done at the tertiary medical center. Participants  The medical records of prolactinomas patients who underwent endoscopic endonasal surgery between March 2008 and August 2016 were reviewed. Main Outcome Measures  Demographic information, tumor characteristics, and treatment characteristics and outcomes were collected. Statistical analysis was performed using chi-squared test or Student's t -test as applicable. Results  Seventy-nine patients were identified, 22 males and 57 females. The average age for males was 38 years and for females was 35 years. Males were more likely to present with decreased libido ( p  < 0.0001), whereas females more often presented with galactorrhea ( p  < 0.0001) and menstrual irregularities. Tumor size was larger in males ( p  = 0.0044) with higher likelihood of suprasellar extension ( p  = 0.0409) and cavernous sinus invasion ( p  = 0.0026). Males were more likely to have a subtotal resection rather than gross total resection ( p  = 0.0086) and less likely to have normalization of prolactin levels following surgery ( p  = 0.0019) Conclusion  Male prolactinoma patients tend to have larger tumors with more aggressive features. This may have a role in the differences in outcomes noted in this study.

Entities:  

Keywords:  endoscopic; gender; pituitary adenomas; prolactinoma

Year:  2017        PMID: 30009121      PMCID: PMC6043172          DOI: 10.1055/s-0037-1615748

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  29 in total

Review 1.  Growth-hormone and prolactin excess.

Authors:  A Colao; G Lombardi
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

Review 2.  Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient.

Authors:  O Serri; D Noiseux; F Robert; J Hardy
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

3.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.

Authors:  E Delgrange; J Trouillas; D Maiter; J Donckier; J Tourniaire
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

4.  Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.

Authors:  E Delgrange; G Sassolas; G Perrin; M Jan; J Trouillas
Journal:  Acta Neurochir (Wien)       Date:  2005-03-14       Impact factor: 2.216

Review 5.  Dopamine agonist-resistant prolactinomas.

Authors:  Michael C Oh; Manish K Aghi
Journal:  J Neurosurg       Date:  2011-01-07       Impact factor: 5.115

6.  Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth.

Authors:  Etienne Delgrange; Alexandre Vasiljevic; Anne Wierinckx; Patrick François; Emmanuel Jouanneau; Gérald Raverot; Jacqueline Trouillas
Journal:  Eur J Endocrinol       Date:  2015-03-19       Impact factor: 6.664

7.  Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study.

Authors:  K Kovacs; L Stefaneanu; S Ezzat; H S Smyth
Journal:  Arch Pathol Lab Med       Date:  1994-05       Impact factor: 5.534

8.  Age-related and gender-related occurrence of pituitary adenomas.

Authors:  T Mindermann; C B Wilson
Journal:  Clin Endocrinol (Oxf)       Date:  1994-09       Impact factor: 3.478

9.  A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.

Authors:  J Webster; G Piscitelli; A Polli; C I Ferrari; I Ismail; M F Scanlon
Journal:  N Engl J Med       Date:  1994-10-06       Impact factor: 91.245

Review 10.  Diagnosis and Treatment of Pituitary Adenomas: A Review.

Authors:  Mark E Molitch
Journal:  JAMA       Date:  2017-02-07       Impact factor: 56.272

View more
  3 in total

1.  Predictive modeling for pituitary adenomas: single center experience in 501 consecutive patients.

Authors:  A L Pappy; A Savinkina; C Bicknese; S Neill; N M Oyesiku; A G Ioachimescu
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 2.  Aggressive prolactinoma (Review).

Authors:  Ana Valea; Florica Sandru; Aida Petca; Mihai Cristian Dumitrascu; Mara Carsote; Razvan-Cosmin Petca; Adina Ghemigian
Journal:  Exp Ther Med       Date:  2021-11-24       Impact factor: 2.447

3.  Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis.

Authors:  Xiangming Cai; Junhao Zhu; Jin Yang; Chao Tang; Zixiang Cong; Chiyuan Ma
Journal:  Chin Neurosurg J       Date:  2022-04-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.